D. K. Armstrong

The role of nonrandomized trials in the evaluation of oncology drugs

Richard Simon, GM Blumenthal, Rothenberg Ml et al. · Clinical Pharmacology & Therapeutics · 2015 · 65 citations

Medicine, Oncology, Pharmacology +17

Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer

A. Nickles Fader, Luis A. Díaz, D. K. Armstrong et al. · Gynecologic Oncology · 2016 · 44 citations

Medicine, Gynecology, Oncology +15

Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse

D. K. Armstrong, Annette Bicher, Robert L. Coleman et al. · Journal of Clinical Oncology · 2008 · 35 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

W ten Bokkel Huinink, J. Carmichael, D. K. Armstrong et al. · PubMed · 1997 · 30 citations

Medicine, Gynecology, Oncology +12

BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

Melissa M. Thrall, Holly H. Gallion, Richard J. Kryscio et al. · International Journal of Gynecological Cancer · 2006 · 30 citations

Medicine, Genetics, Oncology +17